- Home
- MLNK vs ABCL Comparison
MLNK vs ABCL Comparison
Compare MLNK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- ABCL
- Stock Information
- Founded
- MLNK 1998
- ABCL 2012
- Country
- MLNK United States
- ABCL Canada
- Employees
- MLNK N/A
- ABCL N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- ABCL Health Care
- Exchange
- MLNK Nasdaq
- ABCL Nasdaq
- Market Cap
- MLNK 1.3B
- ABCL 1.1B
- IPO Year
- MLNK 2021
- ABCL 2020
- Fundamental
- Price
- MLNK $19.81
- ABCL $4.59
- Analyst Decision
- MLNK Hold
- ABCL Strong Buy
- Analyst Count
- MLNK 8
- ABCL 5
- Target Price
- MLNK $21.21
- ABCL $8.00
- AVG Volume (30 Days)
- MLNK 1.3M
- ABCL 6.4M
- Earning Date
- MLNK 08-11-2025
- ABCL 08-07-2025
- Dividend Yield
- MLNK N/A
- ABCL N/A
- EPS Growth
- MLNK N/A
- ABCL N/A
- EPS
- MLNK N/A
- ABCL N/A
- Revenue
- MLNK $325,891,000.00
- ABCL $32,875,999.00
- Revenue This Year
- MLNK $6.21
- ABCL N/A
- Revenue Next Year
- MLNK $5.66
- ABCL $71.11
- P/E Ratio
- MLNK N/A
- ABCL N/A
- Revenue Growth
- MLNK 5.96
- ABCL N/A
- 52 Week Low
- MLNK $15.49
- ABCL $1.89
- 52 Week High
- MLNK $25.33
- ABCL $5.82
- Technical
- Relative Strength Index (RSI)
- MLNK 74.95
- ABCL 56.32
- Support Level
- MLNK $19.75
- ABCL $3.93
- Resistance Level
- MLNK $19.85
- ABCL $4.77
- Average True Range (ATR)
- MLNK 0.33
- ABCL 0.34
- MACD
- MLNK 0.44
- ABCL -0.04
- Stochastic Oscillator
- MLNK 99.07
- ABCL 61.11
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.